Scarica l'app Stockscreener
2.49
10.67%
0.24
Pre-mercato:
2.43
-0.06
-2.41%
Precedente Chiudi:
$2.25
Aprire:
$2.3
Volume 24 ore:
198.86K
Relative Volume:
1.14
Capitalizzazione di mercato:
$12.28M
Reddito:
-
Utile/perdita netta:
$-23.92M
Rapporto P/E:
-0.0989
EPS:
-25.1834
Flusso di cassa netto:
$-22.74M
1 W Prestazione:
+19.71%
1M Prestazione:
-3.49%
6M Prestazione:
-77.35%
1 anno Prestazione:
-91.34%
Intervallo 1D:
$2.27
$2.50
Intervallo di 1 settimana:
$1.97
$2.50
Portata 52W:
$1.79
$28.75
Moleculin Biotech Inc Stock (MBRX) Company Profile
Nome
Moleculin Biotech Inc
Settore
Industria
Telefono
713-300-5160
Indirizzo
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
2.49 | 12.28M | 0 | -23.92M | -22.74M | -25.18 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-09 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-12 | Downgrade | Maxim Group | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Sell Signal: Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Moleculin at Roth Conference: Annamycin’s Market Potential By Investing.com - Investing.com Canada
MBRX: Annamycin's phase III AML trial nears key data, highlighting strong efficacy and zero cardiotoxicity - TradingView
MBRX: Annamycin's phase III AML trial nears key data, highlighting its efficacy and safety advantages - TradingView
MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus
Moleculin enrolls 45th patient in pivotal AML trial By Investing.com - Investing.com Canada
Moleculin Biotech Reports 40% Remission Rate in Early Phase 3 AML Study for Annamycin, Accelerating Toward 90 Patient Enrollment 12 - Minichart
Moleculin Biotech (MBRX) Advances Phase 2B/3 Trial for Acute Mye - GuruFocus
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - Bitget
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout - TipRanks
Moleculin enrolls 45th patient in pivotal AML trial - Investing.com
Moleculin Biotech, Inc. Prepares for Key Interim Results in Pivotal AML Trial with 40% Early Remission Rate - Quiver Quantitative
Moleculin Hits 45-Subject Milestone, Sets Mid-2026 MIRACLE Interim Readout - TradingView
Leukemia drug study reaches key 45-patient mark with results due mid-2026 - Stock Titan
Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial - Stock Titan
If You Invested $1,000 in Moleculin Biotec (MBRX) - Stock Titan
MBRX SEC FilingsMoleculin Biotec 10-K, 10-Q, 8-K Forms - Stock Titan
Moleculin Biotech, Inc.: Fundamental Analysis and Financial Ratings | MOL0 | US60855D4088 - marketscreener.com
MBRX Expects Cash Reserves to Fund Operations Through Q3 2026 - GuruFocus
Optimism Surrounds Moleculin's (MBRX) MIRACLE Trial Progress - GuruFocus
Moleculin Biotech Updates Investors with New Corporate Presentation - TipRanks
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 - The Manila Times
Moleculin Biotech Reports 40% Preliminary CRc Rate in First 30 Patients of MIRACLE Trial for Relapsed/Refractory AML - Quiver Quantitative
[8-K] Moleculin Biotech, Inc. Reports Material Event | MBRX SEC FilingForm 8-K - Stock Titan
Moleculin Biotech reports FY2025 net loss $33.6M, cash $8.9M; MIRACLE interim CRc 40% - TradingView
Moleculin (Nasdaq: MBRX) details 2025 loss and MIRACLE AML trial progress - Stock Titan
MBRX Forecast, Price Target & Analyst Ratings | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Moleculin Biotech 2025 Annual Report: Annamycin Clinical Trials & Pipeline Update - Minichart
Moleculin Biotech 10-K: No Revenue, Net Loss $33.6M, Ops Loss $25.1M - TradingView
Moleculin Biotech (NASDAQ: MBRX) outlines Annamycin Phase 3 AML strategy - Stock Titan
Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Moleculin to Present at 38th Annual ROTH Conference - The Manila Times
Moleculin Biotech Inc expected to post a loss of $6.11 a shareEarnings Preview - TradingView
Moleculin leaders set for March 24 ROTH healthcare investor chat - Stock Titan
Net current asset value per share of Moleculin Biotech, Inc. – FWB:MOL0 - TradingView
Moleculin Reports Second Quarter 2024 Financial Results and Prov - GuruFocus
MBRX Should I Buy - Intellectia AI
Moleculin Biotech releases CEO update on leukemia trial By Investing.com - Investing.com India
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study - The Manila Times
Moleculin Biotech releases CEO update on leukemia trial - Investing.com
Moleculin Biotech (MBRX) seeks vote on 6.37M warrants and name change - Stock Titan
Form DEF 14A Moleculin Biotech For: 9 March By Investing.com - Investing.com Canada
Maxim Group Sticks to Their Buy Rating for Moleculin Biotech (MBRX) - The Globe and Mail
Pullback Watch: Will Moleculin Biotech Inc benefit from geopolitical trendsMarket Activity Report & Safe Capital Growth Tips - baoquankhu1.vn
Moleculin Announces Closing of up to $16.5 Million Public Offering - Quantisnow
Aug Reactions: Will Moleculin Biotech Inc benefit from geopolitical trends2025 Fundamental Recap & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
MBRX PE Ratio & Valuation, Is MBRX Overvalued - Intellectia AI
Moleculin Biotech (MBRX) seeks OK for 6.37M warrants, $15.3M proceeds - Stock Titan
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin Biotech Inc Azioni (MBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):